Volver al Panel







Gilead Sciences, Inc. (GILD)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
GILD Intraday
No data available
SímboloGILD
Fecha de SalidaJan 22, 1992
CEOMr. Daniel Patrick O'Day
Empleados a Tiempo Completo17k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNasdaqGS
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -0.06% | -0.10 US$ |
| 5 Días | -0.98% | -1.65 US$ |
| 1 Mes | +8.37% | +12.86 US$ |
| 6 Meses | +23.87% | +32.07 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de GILD...
Estadísticas Clave
Cap. de Mercado
206.43B
Relación P/E
N/A
Rend. de Div.
1.97%
Máx. 52 Semanas
$176.58
Mín. 52 Semanas
$116.88
Consenso de Analistas
CONSENSOCompra
ALCISTA2177.8%
NEUTRAL518.5%
BAJISTA13.7%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$131.00
$131.00
Objetivo Máx.
$200.00
$200.00
Actual$166.43
Objetivo Prom.$175.92
Recomendaciones de Analistas
Precio Objetivo:$175.92($131.00 - $200.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre GILD
Únase a la comunidad para compartir su análisis
Últimas Noticias para GILD

Mizuho Securities Adjusts Gilead Sciences Price Target to $182 From $170, Maintains Outperform Rating
MT Newswires•20 nov 2026, 15:00

Is It Too Early To Buy Insmed Stock?
Trefis•20 nov 2026, 14:29

How Investors Are Reacting To Gilead Sciences (GILD) HIV Prevention Expansion
Simply Wall St.•19 nov 2026, 13:12

Should You Buy Exelixis Stock For Its Cash?
Trefis•19 nov 2026, 11:43

Where Could Gilead's Next Growth Come From?
Trefis•19 nov 2026, 11:43

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks•18 nov 2026, 13:00
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
GuruFocus.com•18 nov 2026, 11:05
Gilead Sciences Insider Sold Shares Worth $4,775,527, According to a Recent SEC Filing
MT Newswires•18 nov 2026, 08:29